The application relates to a compound of Formula (I′) or (I):

##STR00001##

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I′) or (I), and a method of treating or preventing a disease in which SSAO plays a role.

Disclosed herein are processes for the preparation of compounds of formula (I) from one or more bio-derived reactants, and their use as base oils:

(R.sub.1-A).sub.b-(CH.sub.x).sub.a(CHR.sub.2).sub.m(C(R.sub.4R.sub.5)).sub.n(CHR.sub.3).sub.o(CH.sub.y).sub.c-(A-R.sub.1).sub.d(I)

wherein a and c are independently 0 or 1, b and d are independently 1 or 2, x and y are independently 1 or 2, dependent upon the values of a-d, m and o are independently 0 or 1, n is an integer of 0-6, and each A is independently an unsaturated furan ring, a partially saturated furan ring, a saturated furan ring, or (CH.sub.2).sub.4. Also, R.sub.1, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are independently selected from the group consisting of H and alkyl groups having 1 to 18 carbon atoms, with a proviso that at least one of R.sub.2, R.sub.3, R.sub.4, and R.sub.5 is not hydrogen, and the total carbon content of the compound of formula (I) is in the range of 20-62.

Disclosed herein are processes for the preparation of compounds of formula (I) from one or more bio-derived reactants, and their use as base oils:

(R.sub.1-A).sub.b-(CH.sub.x).sub.a(CHR.sub.2).sub.m(C(R.sub.4R.sub.5)).sub.n(CHR.sub.3).sub.o(CH.sub.y).sub.c-(A-R.sub.1).sub.d(I)

wherein a and c are independently 0 or 1, b and d are independently 1 or 2, x and y are independently 1 or 2, dependent upon the values of a-d, m and o are independently 0 or 1, n is an integer of 0-6, and each A is independently an unsaturated furan ring, a partially saturated furan ring, a saturated furan ring, or (CH.sub.2).sub.4. Also, R.sub.1, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are independently selected from the group consisting of H and alkyl groups having 1 to 18 carbon atoms, with a proviso that at least one of R.sub.2, R.sub.3, R.sub.4, and R.sub.5 is not hydrogen, and the total carbon content of the compound of formula (I) is in the range of 20-62.

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

The invention relates to surfactants of general formula (I) in which R.sup.1 and R.sup.2 represent independently of one another represent H and SO.sub.3.sup.X+ with the proviso that at least one of R.sup.1 and R.sup.2 is not H, n and m represent independently from each other numbers from 0-21 under the proviso that 4<n+m<26, and X.sup.+ represents a charge-balancing anion. The surfactants can be incorporated into detergents or cleaning agents, have excellent technological application properties and can be produced based on renewable raw materials.

The invention relates to surfactants of general formula (I) in which R represents a linear or branched alkyl, alkenyl, alkylaryl or alkenylaryl group having 5-25 C atoms and X.sup.+ represents a charge-balancing cation. The surfactants can be incorporated into detergents or cleaning agents, have excellent technological application properties and can be produced based on renewable raw materials.

The application relates to a compound of Formula (I) or (I): ##STR00001##
or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I) or (I), and a method of treating or preventing a disease in which SSAO plays a role.

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.